Pyrosequencing was also performed to verify the presence of the sW74* mutant. The corresponding mutant constituted MK-8669 manufacturer 83.1% of the viral population. Two samples from HBsAg-positive stages were

submitted for PCR and sequence analysis. The sW74* mutation was not present in the HBsAg-positive samples. For the study of the phenotypic changes in HBsAg in the sT125A mutant, 5 μg of a plasmid (pCMV-sT125A or pCMV-S) was transfected into Huh-7 cells. Northern blot analysis showed that a greater amount of S messenger RNA (mRNA) was detected in the pCMV-sT125A–transfected cells versus the pCMV-S–transfected cells (1.5- and 2.2-fold greater in two independent experiments; Fig. 3A). Immunofluorescence analysis using a polyclonal anti-HBs antibody detected both sT125A and wild-type surface antigens in the transfected Huh-7 cells (Fig. 3B). The apparent transfection efficiency was approximately 5% in both sets of experiments. However, western blot analysis detected wild-type surface proteins [glycoprotein 27 (GP27) and protein 24 (P24)] but not the sT125A mutant surface protein. To assess the antigenicity of HBsAg secreted into the medium, we performed a slot blot analysis with the culture medium. A small amount of the mutant HBsAg was detected by two monoclonal antibodies (MAHBs1 and MAHBs2), but it was not detected by the third one (MAHBs3) or the polyclonal antibody. A radioimmunoassay Seliciclib purchase (Ausria II) and an enzyme immunoassay (Enzygnost HBsAg 5.0) were then

used to detect HBsAg in the culture medium. The Ausria assay failed to detect the mutant HBsAg, but the Enzygnost assay detected the antigen, albeit in a low positive range (the signal/cutoff ratio was 13.37 for sT125A and 1380 for the wild type). To determine the phenotypic alterations of the sW74* mutant, we transfected 5 μg of pCMV-sW74* or pCMV-S into Huh-7 cells. Northern blot analysis showed similar expression levels of the S mRNA (Fig. 4A). However, the polyclonal anti-HBs antibody failed to detect the sW74* mutant in either immunofluorescence analysis (Fig. 4B) or western analysis.

The mutant HBsAg could not be detected by either the Ausria assay or the Enzygnost assay. The goal of anti-HBV treatment has changed significantly in the past decades. Before the clinical availability of interferon and oral MCE公司 antiviral agents, cytoprotective agents were considered effective because of their ability to normalize or reduce ALT levels.20, 21 Since the approval of regular interferon for anti-HBV treatment, HBeAg seroconversion has been used as an important endpoint for the evaluation of effective treatment.22 Although HBeAg seroclearance is usually accompanied by a significant reduction of the HBV DNA level, a significant proportion of patients continue to have high and fluctuating HBV DNA levels, and this results in HBeAg-negative hepatitis.23 Molecular analysis has revealed the selection of mutants that fail to secrete HBeAg (precore stop codon mutants).